All News
New Research Demonstrates Impact of RISE Registry Data on Rheumatology Outcomes
ACR Press Release
New research presented at ACR Convergence 2025 highlights how the Rheumatology Informatics System for Effectiveness (RISE) registry—the nation’s largest collection of electronic health record data from rheumatology practices—is driving transformative improvements in quality, safety, and patient outcomes across rheumatic and musculoskeletal diseases.
Read Article
#1639
In 2 lupus cohorts (n=619), 1 in 4 had mismatch between self-reported & measured physical function.
Higher BMI, disease activity & depression linked to underreporting ability ➡️ self-report ≠ performance! Important for SLE care & research. @RheumNow #ACR25 https://t.co/kMlChreJPh
Mrinalini Dey DrMiniDey ( View Tweet)
GLP1 receptors are present on cartilage, synovial and specific cells such as macrophages.
Also endogenous GLP1 seemed to protect the cartilage in animal models
#ACR25 @RheumNow https://t.co/ekNWbtPO4b
Links:
Bella Mehta bella_mehta ( View Tweet)
The axSpA Registry of Ireland (ASRI): 10% reported depression, w/ higher prev in older cohorts.
Pts w/ depression had ⬆️peripheral involvement, ⬆️dse activity & poor functional status
💡Consider the impact of non-inflamm factors in dse burden
#ACR25 @RheumNow Abs1409 https://t.co/yDfHA24M6e
sheila RHEUMarampa ( View Tweet)
NEREA registry study on mortality in progressive pulmonary fibrosis in SARD-ILD. 158 patients. Median survival 7.8 years. DMARD use associated improved mortality. @RheumNow #ACR25 Abstr#1024 https://t.co/rK1caGi2r4
Richard Conway RichardPAConway ( View Tweet)
POETYK-PsA 1 & 2 Phase 3 RCT TYK2i Deucravacitinib
Pooled analysis 640+pts PBO vs. 640+pts DEUCRA 6mg QD
MDA 12% vs 22%
All elements of MDA response sig different except for Leeds enthesitis index
DAPSA Remission 2% vs. 9%
PsARC 42% vs. 61%
PASDAS -1 vs. -1.7
mCPDAI -1.2 vs. -1.9 https://t.co/OTOFxTOrRp
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
GLP-1 receptor agonists reduce mortality in PsA
Tsibadze et al retrospectively compared ~4k PsA on GLP-1 to ~86k PsA not
After propensity matching, those treated with GLP-1:
- lower risk MACE
- lower risk overall death
@RheumNow #ACR25 Abst 0849 https://t.co/EuojrDq0Fj
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Abstract 0874:
At wk16, deucravacitinib (vs placebo) showed greater efficacy in multiple #PsA disease activity measures
🔹 ↑ MDA, DAPSA LDA/remission, and PsARC responses
🔹 Greater ↓in PASDAS and mCPDAI
🔹 Benefits seen in both men and women
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Open-label MTX vs. Toci in GCA in METOGiA
Wk 78:
37% w/o relapse in MTX arm
46% w/o relapse in Toci arm
MTX was NOT non-inferior to Toci
Toci superior in 2ndary endpoints
Cumulative doses GC not significantly different
#ACR25 #ACRBest @RheumNow Abst 0891 https://t.co/lCaP4EdJ9C
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
HOPE for Pts w #fibromyalgia #FM
#Transcutaneous #electrical #nerve #stimulation + #physio
Is
Better than #PT alone
#Pragmatic #cluster #randomized #trial
Answered impt question
Does #TENS help Pts w #fibro
Too ba noTENS sham
Abst#LB03 #ACR25 #ACRBest @RheumNow @ACRheum https://t.co/fGyAugFtcN
Janet Pope Janetbirdope ( View Tweet)
A randomized trial of app-based behavioral (acceptance and commitment) therapy (ACT) showed reduced pain interference and affective distress in axial SpA compared to standard of care. Acceptance was moderate, but impact was meaningful. Abstract 1461 @RheumNow #ACR25 https://t.co/sF5Ldtc61R
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#1077 More health literacy work from our group!
995 people with inflammatory arthritis: lower health literacy linked to higher absenteeism & presenteeism
Those with highest HLQ scores were mostly retired with better engagement in care
@RheumNow #ACR25
Come check out our poster! https://t.co/CaqzkjMWYB
Mrinalini Dey DrMiniDey ( View Tweet)
This retrospective study evaluated incidence of MACE & mortality among PsA pts on GLP-1RAs vs non-GLP-1RAs
After propensity score matching, pts on GLP-1RAs = ⬇️ risk of developing MACE & ⬇️ mortality vs. non GLP-1RAs
Interesting data, More research reqd
#ACR25 @RheumNow Abs0849 https://t.co/hiPpQH0K3O
Links:
sheila RHEUMarampa ( View Tweet)
#0851
Urinary Tenascin C predicts kidney function loss in lupus nephritis
170 AMP-LN patients: Tenascin C (from renal myofibroblasts) was the top predictor of eGFR decline (HR 4.6)
Proteomic 11-marker risk score (AUC 0.91) outperformed proteinuria for prognosis #ACR25 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR25 Abstr#1525 Find me at poster hall. Super-responders exist with rituximab, not just confined to CAR-T! Our cohort study = 23/114 (20%) had resp duration >3-yrs; 15/23 were IS-Free. Poor prognostics (Non-White, APS) & shorter #SLE duration predicted super-tesponse @RheumNow https://t.co/nJQFmiIj2n
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Time for the 2nd plenary session! 🎤
#0849 GLP-1 receptor agonists in #PsA linked with lower mortality & fewer major cardiac events in >90K patients.
Promising data for inflammation, weight & heart health in PsA care. @RheumNow #ACR25 https://t.co/8zyrSrumOP
Mrinalini Dey DrMiniDey ( View Tweet)
This morning in the plenary, same theme, but in PsA:
Similar metabolic/CV concerns
Similarly benefit from GLP-1 RA
looking at TriNetX data again, reduced MACE
Now prospective trials in rheum disease, for both metabolic benefits & disease activity?
#ACR25 ABST0849 @RheumNow https://t.co/DHZN1hwbIG
David Liew drdavidliew ( View Tweet)
Why do we need to identify early PsA?
🔅Improve symptoms
🔅Prevent radiographic progression
🔅Preserve function
☝️Recent data show that erosions are prevalent in early PsA but lower if symptom duration is <6 mos.
#ACR25 @RheumNow https://t.co/sEGXzd8RiD
Links:
sheila RHEUMarampa ( View Tweet)
RA may age the immune system by nearly two decades.
IgG glycome profiles showed inflammatory aging even in early RA, tied to low fitness & high inflammation.
Improving muscle & fitness may help reverse this biologic clock.
@RheumNow #ACR25 Abstract #0835
Jiha Lee JihaRheum ( View Tweet)
Abstract 0842
💡 Urinary biomarkers as the next frontier for monitoring lupus nephritis activity
🔹 Proteinuria didn’t track w/ histologic activity
🔹 IL-16 & sCD163 correlated at baseline only
🔹 Urinary Tenascin C & BAFF correlated w/ activity at 1 yr
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
